TICKERNERD
Menu
TOVXTOVXHealthcare · Biotechnology

TOVX Stock Forecast: Theriva Biologics, Inc. Price Predictions for 2026-2027

Last close, 13 Oct 2026
$0.22
−1.95% on the day

The 2 Wall Street analysts covering Theriva Biologics, Inc. hold a median 12-month price target of $2.5 — +1059.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 12 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$10.1M
Ticker Nerd rank
29 / 100
Median analyst target
$2.50
Analysts covering
2
Revenue$0.0
Operating income−$3.3M
Net income−$3.2M
Free cash flow−$3.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.0%
1M
−13.7%
YTD
+2.7%
1Y
−52.1%
From 52W high
−74.3%
From 52W low
+19.8%
$0.18
$0.84
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TOVX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Theriva Biologics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Oct 2026
29 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
92
Growth
67
Accruals
52
Quality
49
Momentum
37
Value
27
Revisions
27
Volatility
23
Issuance
11

Size (92): Smaller than most of the companies we track.

Issuance (11): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TOVX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TOVX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00Jan 26Apr 26Jul 26Oct 26TOVXHigh $4.00Median $2.50Low $1.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $1.00Median $2.50High $4.00

The green dot is the last close — the median target sits +1059.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
31 Mar 2026Maxim GroupUpgradeBuy—
8 May 2025Maxim GroupDowngradeHold—
13 Nov 2024Maxim GroupMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TOVX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TOVX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 13 Oct 2026, Theriva Biologics, Inc. returned −52.1% against +18.6% for the S&P 500, dividends included.

TOVX vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26TOVXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TOVX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Theriva Biologics, Inc. (TOVX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.3×

Cheaper than 72% of US stocks

Price / sales
33.6×

Cheaper than 7% of US stocks

Price / book
0.8×

Cheaper than 77% of US stocks

EV / EBITDA
−0.2×

Cheaper than 63% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−4022.0%

Higher than 3% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−101.9%

Higher than 13% of US stocks

Return on assets
−21.3%

Higher than 19% of US stocks

Dividend yield
2726.0%

Higher than 99% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Theriva Biologics, Inc. (TOVX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Theriva Biologics, Inc. has a market value of $10.1M and an enterprise value of $2.3M.

  • Revenue in the twelve months to 30 June 2026: $300K. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$11.6M, a −3872.7% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$12.8M.

  • Shares outstanding: 45.9M.

  • Trailing P/E: 0.3×; forward P/E: −1.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 2726.03%, paying out 0% of earnings.

  • Theriva Biologics, Inc. employs 15 people — $20K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Oct 2026

Data provided by Twelve Data

Peers

TOVX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TOVXTheriva Biologics, Inc.$10.1M
29
VTGNVistagen Therapeutics, Inc.$10.1M
31
SNTISenti Biosciences Holdings, Inc.$9.9M
61
GDTCCytoMed Therapeutics Ltd.$9.6M
29
MTVAMetaVia, Inc.$9.6M
17
PHIOPhio Pharmaceuticals Corp.$10.7M
19
LSTALisata Therapeutics, Inc.$9.5M
56

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Theriva Biologics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TOVX news & analysis

Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine

GlobeNewsWire · 30 Sept 2026positive

Theriva Biologics announced that detailed results from the VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic cancer patients were published in Nature Medicine after rigorous peer review. The company noted the data support an immune-mediated mechanism of action and that repeated VCN-01 dosing is being evaluated in the VIRAGE2 Phase 2a trial.

Why it matters — Publication in the premier journal Nature Medicine validates the VIRAGE study and supports continued evaluation of VCN-01, a key pipeline candidate, in metastatic pancreatic cancer.

Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma

GlobeNewsWire · 6 Aug 2026positive

Theriva Biologics announced that the first patient has been dosed in the VIRAGE2 Phase 2a clinical trial, which evaluates more frequent dosing of VCN-01 (zabilugene almadenorepvec) in first-line patients with metastatic pancreatic ductal adenocarcinoma. The exploratory study is designed to refine the VCN-01 dosing regimen for potential evaluation in a future pivotal Phase 3 trial.

Why it matters — A TOVX watcher would care because this marks clinical progress for VCN-01 and generates data that could inform the design of a future pivotal Phase 3 trial in metastatic pancreatic cancer.

FAQ

Frequently asked questions about TOVX stock

What is the TOVX stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Theriva Biologics, Inc. have a median 12-month price target of $2.5, with estimates ranging from $1 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TOVX stock a buy right now?

Of the 2 analysts covering Theriva Biologics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Theriva Biologics, Inc. 29 out of 100 across roughly 4,600 US stocks as at 12 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TOVX?

As at 12 Oct 2026, Theriva Biologics, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (92 of 100).

Will TOVX stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +1059.0% from the last close, and Ticker Nerd's factor model ranks Theriva Biologics, Inc. 29 out of 100 as at 12 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TOVX stock forecast for 2030?

No analyst covering Theriva Biologics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TOVX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $4 over the next 12 months.

How has TOVX stock performed over the past year?

Theriva Biologics, Inc. returned -52.1% over the 12 months to 13 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Theriva Biologics, Inc. do?

Theriva Biologics Inc. is a clinical-stage biotechnology company focused on developing therapeutics for cancer and related diseases with significant unmet medical needs.

What is the latest news on TOVX?

The most recent item we track (GlobeNewsWire, 30 Sept 2026): "Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine". Theriva Biologics announced that detailed results from the VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic cancer patients were published in Nature Medicine after rigorous peer review. The company noted the data support an immune-mediated mechanism of action and that repeated VCN-01 dosing is being evaluated in the VIRAGE2 Phase 2a trial.

Company

About Theriva Biologics, Inc.

Theriva Biologics Inc. is a clinical-stage biotechnology company focused on developing therapeutics for cancer and related diseases with significant unmet medical needs. The company’s current pipeline centers on oncolytic adenovirus technology, including VCN-01, an investigational program designed to selectively attack tumor cells and support the delivery of co-administered cancer therapies. Theriva Biologics is also advancing microbiome-related candidates such as SYN-004 and SYN-020, which are intended to help preserve the gut microbiome during antibiotic treatment and address complications linked to microbiome disruption. Its programs span oncology, infectious disease prevention, and gastrointestinal health, reflecting a diversified approach to therapeutic development. Based in Rockville, Maryland, Theriva Biologics operates as a research-driven developer of novel treatment platforms for areas where current options remain limited.

CEO Mr. Steven A. Shallcross CPA · 15 employees · United States · https://therivabio.com